[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-457529-105":59,"doc-detail-457529-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","antimicrobial-stewardship-strategies-for-implementing-the-2019-eucast-i-definition","Antimicrobial stewardship strategies for implementing the 2019 EUCAST “I” definition","","2019 年，欧洲抗菌药物药敏试验委员会（EUCAST）将“I”类别由“中介敏感”重新定义为“敏感，且需增加暴露”。研究在医院层面落实标准措施，并建立包含主动监测的多维度执行方案，以评估其对抗菌药物使用与相关临床结局的影响。方法包括修订给药表、选择性报告、结构化电子医嘱与全院沟通，并在 2022 年 2 月至 2024 年 7 月开展基于 13 条临床规则的药师用药适宜性审核。结果显示建议采纳率高且广谱药物用量维持稳定或下降，ID 会诊显著增加，医院获得性 CDAD 稳定。",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antimicrobial-stewardship-strategies-for-implementing-the-2019-eucast-i-definition/457529/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antimicrobial-stewardship-strategies-for-implementing-the-2019-eucast-i-definition/457529.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"2019 EUCAST “I”定义与先前“中介敏感”有何不同？","Question",{"text":113,"@type":114},"2019 年 EUCAST 将“I”类别从“intermediate susceptibility”调整为“susceptible, provided increased exposure”，强调在敏感前提下需要更高的抗生素剂量暴露。部分物种同时移除了“S”类别。","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"该研究实施了哪些关键策略来支持“2019 EUCAST I”落地？",{"text":118,"@type":114},"研究引入了修订给药表、选择性报告、结构化电子用药医嘱以及全院沟通，并在药师基于用药适宜性审核服务中启动主动监测，使用 13 条临床规则筛查不恰当处方，由药师向医师提出建议，且药学与微生物科共同协作。",{"name":120,"@type":111,"acceptedAnswer":121},"主要结果体现在哪些方面？",{"text":122,"@type":114},"针对铜绿假单胞菌感染，基于标准实施措施对 2019 EUCAST “I”指南的自发采纳率达到 78%；30 个月共提出 1688 条建议且 87% 被接受。广谱抗菌药（尤其美罗培南）用量保持稳定或下降，感染科会诊在干预后显著增加，医院获得性 CDAD 保持稳定。","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},457529,1791376514,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Van den Broucke etal. BMC Infectious Diseases (2026) 26:24 BMC Infectious Diseases  \n[https://doi.org/10.1186/s12879-025-11943-x](https://doi.org/10.1186/s12879-025-11943-x)  \nRESEARCH Open Access  \nAntimicrobial stewardship strategies for implementing the 2019 EUCAST“I”definition  \nEvelyneVan den Broucke 1,2*, Charlotte Quintens1, Willy E. Peetermans3,4, Eric Van Wijngaerden3,4, Otto Van de gaer5, Stefanie Desmet3,5 and Isabel Spriet1,2  \nAbstract  \nBackground In 2019, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) redefined the“I” category from “intermediate susceptibility” to “susceptible, provided increased exposure”. This shift emphasizes higher antibiotic dosing, alongside removal of the“S” category for some species. Our hospital implemented standard measures and an active monitoring program to support this change. This study evaluates the impact of this multifaceted strategy.  \nMethods A revised dosing table, selective reporting, structured electronic medication orders and hospital-wide communication were introduced. In February 2022, an active monitoring program with 13 clinical rules was implemented in our pharmacy-based Check of Medication Appropriateness service, continuously screening patients’records for inappropriate antimicrobial prescriptions, with pharmacists sending recommendations to physicians. Pharmacy and microbiology departments collaborated to implement this strategy. The number of recommendations and acceptance rates were measured over 30 months (February 2022-July 2024) . A retrospective evaluation assessed spontaneous uptake of standard implementation measures for Pseudomonas infections (February 2022-January 2023) . An interrupted time series analysis compared pre-and post-implementation periods to measure impact on broadspectrum hospital-wide antibiotic consumption, infectious diseases (ID) specialist consultations and hospital acquired Clostridioides difficile associated diseases (CDAD) .  \nResults Spontaneous uptake of 2019 EUCAST“I” guidelines for Pseudomonas infections, based on standard implementation measures, was 78% . Over 30 months, 1688 recommendations were given, with an 87% acceptance rate. Broad-spectrum antimicrobial consumption, especially consumption of meropenem, remained stable or even decreased post-intervention. ID consultations significantly increased post-intervention (p = 0 . 0023) . Hospital acquired CDAD remained stable.  \nConclusion Our multifaceted strategy, including active monitoring, effectively supported the 2019 EUCAST“I”implementation. Selective reporting is important for spontaneous uptake, while clinical rules guided correct antibiotic  \n*Correspondence:  \nEvelyneVan den Broucke [evelyne.vandenbroucke@uzleuven.be](evelyne.vandenbroucke@uzleuven.be)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.","cbCaim18HjsbW7SO","https://ap.wps.com/l/cbCaim18HjsbW7SO","pdf",1758645,"English","# Background\n## Antimicrobial resistance and antimicrobial stewardship goals\n## EUCAST susceptibility categories and selective reporting\n# Methods\n## Revised dosing table and selective reporting\n## Structured electronic medication orders and hospital-wide communication\n## Active monitoring program and clinical rules\n## Outcome measurements and analyses\n# Results\n## Uptake of EUCAST “I” guidelines for Pseudomonas\n## Recommendations, acceptance rate, and antibiotic consumption\n## ID consultations and hospital acquired CDAD\n# Conclusion","[{\"question\":\"2019 EUCAST “I”定义与先前“中介敏感”有何不同？\",\"answer\":\"2019 年 EUCAST 将“I”类别从“intermediate susceptibility”调整为“susceptible, provided increased exposure”，强调在敏感前提下需要更高的抗生素剂量暴露。部分物种同时移除了“S”类别。\"},{\"question\":\"该研究实施了哪些关键策略来支持“2019 EUCAST I”落地？\",\"answer\":\"研究引入了修订给药表、选择性报告、结构化电子用药医嘱以及全院沟通，并在药师基于用药适宜性审核服务中启动主动监测，使用 13 条临床规则筛查不恰当处方，由药师向医师提出建议，且药学与微生物科共同协作。\"},{\"question\":\"主要结果体现在哪些方面？\",\"answer\":\"针对铜绿假单胞菌感染，基于标准实施措施对 2019 EUCAST “I”指南的自发采纳率达到 78%；30 个月共提出 1688 条建议且 87% 被接受。广谱抗菌药（尤其美罗培南）用量保持稳定或下降，感染科会诊在干预后显著增加，医院获得性 CDAD 保持稳定。\"}]","Antimicrobial stewardship strategies for implementing the 2019 EUCAST “I” definition | PDF",1790749619]